Dataset Information


A Bayesian framework for estimating the risk ratio of hospitalization for people with comorbidity infected by SARS-CoV-2 virus.



Estimating the hospitalization risk for people with comorbidities infected by the SARS-CoV-2 virus is important for developing public health policies and guidance. Traditional biostatistical methods for risk estimations require: (i) the number of infected people who were not hospitalized, which may be severely undercounted since many infected people were not tested; (ii) comorbidity information for people not hospitalized, which may not always be readily available. We aim to overcome these limitations by developing a Bayesian approach to estimate the risk ratio of hospitalization for COVID-19 patients with comorbidities.

Materials and methods

We derived a Bayesian approach to estimate the posterior distribution of the risk ratio using the observed frequency of comorbidities in COVID-19 patients in hospitals and the prevalence of comorbidities in the general population. We applied our approach to 2 large-scale datasets in the United States: 2491 patients in the COVID-NET, and 5700 patients in New York hospitals.


Our results consistently indicated that cardiovascular diseases carried the highest hospitalization risk for COVID-19 patients, followed by diabetes, chronic respiratory disease, hypertension, and obesity, respectively.


Our approach only needs (i) the number of hospitalized COVID-19 patients and their comorbidity information, which can be reliably obtained using hospital records, and (ii) the prevalence of the comorbidity of interest in the general population, which is regularly documented by public health agencies for common medical conditions.


We developed a novel Bayesian approach to estimate the hospitalization risk for people with comorbidities infected with the SARS-CoV-2 virus.


PROVIDER: S-EPMC7543407 | BioStudies | 2021-01-01

REPOSITORIES: biostudies

Similar Datasets

2021-01-01 | S-EPMC7946619 | BioStudies
2020-01-01 | S-EPMC7361093 | BioStudies
2020-01-01 | S-EPMC7428172 | BioStudies
2021-01-01 | S-EPMC7833294 | BioStudies
2021-01-01 | S-EPMC7814851 | BioStudies
2020-01-01 | S-EPMC7485801 | BioStudies
2021-01-01 | S-EPMC7794618 | BioStudies
2021-01-01 | S-EPMC7929187 | BioStudies
2020-01-01 | S-EPMC7454409 | BioStudies
2021-01-01 | S-EPMC7926195 | BioStudies